Overview
Hiroaki Shimizu practices in Akita, Japan. Mr. Shimizu is rated as an Experienced expert by MediFind in the treatment of Stroke. His top areas of expertise are Subarachnoid Hemorrhage, Carotid Artery Disease, Moyamoya Disease, Cerebral Artery Bypass Surgery, and Extracranial-Intracranial Bypass Surgery.
His clinical research consists of co-authoring 126 peer reviewed articles. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 17 articles in the study of Stroke.
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Advanced
- Carotid Artery DiseaseMr. Shimizu isAdvanced. Learn about Carotid Artery Disease.
- Cerebral Artery Bypass SurgeryMr. Shimizu isAdvanced. Learn about Cerebral Artery Bypass Surgery.
- Extracranial-Intracranial Bypass Surgery
- Moyamoya DiseaseMr. Shimizu isAdvanced. Learn about Moyamoya Disease.
- Subarachnoid HemorrhageMr. Shimizu isAdvanced. Learn about Subarachnoid Hemorrhage.
- Experienced
- Aortic DissectionMr. Shimizu isExperienced. Learn about Aortic Dissection.
- AstrocytomaMr. Shimizu isExperienced. Learn about Astrocytoma.
- Brain AneurysmMr. Shimizu isExperienced. Learn about Brain Aneurysm.
- Brain TumorMr. Shimizu isExperienced. Learn about Brain Tumor.
- Breast CancerMr. Shimizu isExperienced. Learn about Breast Cancer.
- COVID-19Mr. Shimizu isExperienced. Learn about COVID-19.